Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NeuroVive presents first preclinical NV354 efficacy results in a model for mitochondrial disease

Lund, Sweden, 18 October 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that positive experimental results for NV354, NeuroVive’s preclinical lead candidate in the NVP015 program for mitochondrial diseases, will be presented by Magnus Hansson, NeuroVive’s Chief Medical Officer and Vice President Preclinical and Clinical Development, at the Cold Spring Harbor Laboratory (CSHL) Meeting – The Evolving Concept of Mitochondria: From Symbiotic Origins to Therapeutic Opportunities, on Long Island, New York, October 18-21, 2018.The presentation at the CSHL

Eltel signs a high voltage power line agreement with the Polish power grid company PSE S.A. for a value of about EUR 18.5 million

Eltel’s Polish company Eltel Networks Energetyka S.A. has in a consortium signed an agreement with the Polish power grid company PSE S.A. to deliver a 400 kV overhead line. Eltel’s part of the contract is worth approximately EUR 18.5 million.The new overhead power line will run between Ostrołęka and Stanisławów, with a total length of 105 km. The agreement also includes an upgrade of two substations, design works, right of way and documentation of the delivery. The project has started and will be completed by the end of 2023. The two other partners in the consortium are SPIE ELBUD

Information about the ongoing exercise period for TO3.

As part of our financing strategy and the agreement with L1 Capital, Brighter has distributed free warrants to the company's shareholders to reduce dilution. October 11 to October 25, 2018 is exercise period of Brighter Warrants TO3 during which holders of Warrants can subscribe for shares. One (1) TO3 warrant can be exchanged for one (1) share. The subscription price for the shares is SEK 4. Holders of warrants who have their Warrants registered in custody at a bank or fund commissioner shall contact their bank or fund commissioner if they want to exercise the Warrants and subscribe

Enzymatica AB: Notice of Extraordinary General Meeting in Enzymatica AB (publ)

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press releaseLund on October 18, 2018                                                                                         Notice of Extraordinary General Meeting in Enzymatica AB (publ) The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM") to be held on Monday November 5, 2018 at 09.30 a.m. at Elite Hotel Ideon,

Interim Report January-September 2018

Third quarter 2018 compared to third quarter 2017 · Customer growth was strong and 32,200 (31,200) new customers were added · Net inflow improved by 42 per cent to SEK 8,380 million (5,900) · Operating income increased by 18 per cent mainly due to higher fund commissions, although all income streams improved · Operating expenses rose by 9 per cent mainly due to increased personnel costs as a result of larger development efforts. Full-year costs are still expected to grow by nearly 11 per cent compared to 2017 · Tax on profit for the period was affected by the Swedish Tax

Dustin publishes prospectus relating to its rights issue

NOT FOR DISTRIBUTION OR PRESS RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR SUCH PRESS RELEASE WOULD BE UNAUTHORISED. ADDITIONAL RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Prospectus relating to the rights issue in Dustin Group AB (publ) (”Dustin” or the ”Company”) has been approved and registered by the Swedish Financial Supervisory Authority and is now available at Dustin’s website (www.dustingroup.com), Carnegie Investment Bank’

Ahlstrom-Munksjö completes the acquisition of Caieiras specialty paper mill in Brazil

AHLSTROM-MUNKSJÖ OYJ PRESS RELEASE OCTOBER 18, 2018 at 9:10 Ahlstrom-Munksjö has completed the acquisition of MD Papéis’ Caieiras specialty paper mill in Brazil for a debt free purchase price of about EUR 98 million*. The acquisition significantly strengthens Ahlstrom-Munksjö’s offering in South America and provides further growth opportunities. The acquired business had net sales of about EUR 76 million and comparable EBITDA of EUR 12 million in 2017. Annual synergy benefits of up to EUR 6 million are estimated, mainly arising from optimization of overlapping businesses. The

Citycon’s Financial Reporting Schedule and AGM 2019

CITYCON OYJ   Financial Calendar   18 October 2018 at 9:05 hrsCitycon Oyj’s schedule of the financial reporting in 2019 is the following: Year 2018 full-year Financial Thursday 7 February 2019 at about 9:00 a.m.Report, Financial Statements andthe Report by the Board ofDirectorsYear 2019 three-month Interim Wednesday 17 April 2019 at about 9:00 a.m.ReportYear 2019 six-month Half-Yearly Thursday 11 July 2019 at about 9:00 a.m.ReportYear 2019 nine-month Interim Thursday 24 October 2019 at about 9:00 a.m.Report Citycon Oyj’s Annual General Meeting (AGM)

SYNOSTE Ltd raises €5.1 million to launch its smart skeletal deformation correction technology

(Helsinki, October 18, 2018) – SYNOSTE Ltd, a Finnish medical device company creates smart solutions for patient-friendly bone-lengthening and bone-deformation correction. The company has raised over five million euros to start clinical investigations and to develop new clinical applications. SYNOSTE ’s patented technology platform provides the basis for further disruptive changes in the treatment of congenital, trauma- and tumour-related limb discrepancies, adult and paediatric deformities, and craniomaxillofacial deformations. The new funding was

Ratos AB: Telephone conference 25 October in connection with Interim report

Press release 18 October 2018 The Interim report January-September 2018 will be released on Thursday, 25 October around 08.00 CET. At 11.00 CET a telephone conference will be held, participant connection: UK: +44 20 3008 9813, SE: +46 8 566 426 99, US: +1 855 831 5948. The telephone conference will be webcasted live at www.ratos.se where presentation material will be available as soon as the report is released. The telephone conference will be recorded and available at www.ratos.se. For further information:Helene Gustafsson, Head of IR & Press, +46 8 700 17 98Financial

Axis AB: Interim report January-September 2018

Third quarter · Net sales increased by 20 percent during the third quarter to SEK 2,695 M (2,253). Net sales increased by 13 percent in local currencies. · Operating profit amounted to SEK 460 M (365), which corresponds to an operating margin of 17.1 percent (16.2).  · Net profit for the period amounted to SEK 353 m (278). · Earnings per share amounted to SEK 5.08 (4.01). January - September · Net sales increased by 15 percent during the period to SEK 7,354 M (6,399). Net sales increased by 15 percent in local currencies. · Operating profit amounted to SEK 1,067 M (

Interim-report January – September 2018

Continued strong demand new city district development project has been initiated· Rental income increased to SEK 1,864m (1,688). In an identical portfolio, income rose by approximately 10 per cent. · Net operating income increased to SEK 1,389m (1 230). In an identical portfolio, net operating income rose by approximately 12 per cent. · The surplus ratio was 75 per cent (73). · Profit from property management increased with 25 per cent to SEK 895m (713). · Realised and unrealised changes in value amounted to SEK 6,213m (4,452). · Net lettings during the period totalled SEK

Ahlsell awarded work-site logistics contract for the construction of Karlatornet in Gothenburg

Ahlsell has been awarded the work-site logistics contract for the construction of Karlatornet, the tallest building ever built in the Nordic region. Karlatornet, which is to be built in the new Karlastaden district in Gothenburg, will have 73 floors and be 245 meters high. The tower is expected to be ready for its first residents in 2021 and the new district is planned to be completed a few years later. The contract covers the full logistic solution for the project, and Ahlsell will have some 40 employees involved in the logistics throughout the project time. For Ahlsell, the project

Nomination Committee for ÅF AB (publ) appointed

The following members have, in accordance with the procedure adopted by the Annual General Shareholders Meeting, been appointed to the ÅF Nomination Committee. -              Anders Narvinger, Chairman of the Board              -              Magnus Olofsson, (Chairman of the Nomination Committee) appointed by Stiftelsen ÅForsk -              Johan Strandberg, appointed by SEB Investment Management -              Lilian Fossum Biner, appointed by Handelsbanken Asset Management -              Monica Åsmyr, appointed by Swedbank Robur Fonder -              Niklas Ringby,

Bactiguard receives product approval in Egypt

The product approval for Bactiguard’s urinary (Foley) catheters has been announced by the Egyptian Ministry of Health. This opens new opportunities for Bactiguard in providing effective infection prevention in the most populous country in North Africa and the Middle East.“We are finally through the registration process in Egypt, which started more than an year ago and was longer than expected. This is a breakthrough and together with our distributor Heal Pharma, we can now start the launch activities in the most populous country in the region”, says Jonas Östregård, SVP Sales and continues:

Cxense ASA: Adjustment of purchase price re acquisition of Enreach Solutions Oy by issue of shares

Reference is made to the stock exchange announcement from Cxense ("Cxense" or the "Company") on 30 April 2018 regarding the acquisition of Enreach Solutions Oy.    In connection with the final purchase price adjustment in the transaction agreement, the board of Cxense has today issued 7,576 new shares to Enreach Solutions AB, the seller of Enreach Solutions Oy, in addition to the 123,789 shares issued on 30 April 2018. The new shares were issued at a subscription price of NOK 55.    The share capital increase is expected to be registered with the Norwegian Register of Business

Citycon Oyj’s Interim Report for 1 January – 30 September 2018: Solid operating performance continued and administrative expenses declined significantly.

Citycon Oyj   Interim Report   18 October 2018 at 09:00 hrs- Occupancy remained at a high level of 96.1%.- Successful opening of newest asset Mölndal Galleria in Gothenburg Sweden.- Divestments conducted in 2017 and in 2018 as well as weaker currencies impacted net rental income and EPRA Earnings as expected.- Cost savings initiatives progressed well and administrative expenses decreased significantly by 14% year-on-year.- Fair value change of investment properties was EUR -54.2 million mainly driven by secondary assets in Finland and Norway.- Loan-to-value (LTV) increased to 48.2%

Invitation to presentation of ICA Gruppen’s Q3 report

ICA Gruppen will publish its Q3 report 2018 on Thursday 25 October. In conjunction to this, we are pleased to issue this invitation to a press and analyst telephone conference. ICA Gruppen’s CEO Per Strömberg and CFO Sven Lindskog will present the interim report with the possibility to ask questions afterwards. The presentation can be followed at http://www.icagruppen.se/en/investors Time: Thursday 25 October 2018 at 10.00 CET If you would like to ask questions, please dial in: SE: +46850639549 UK: +442030089816 A recorded version of the audio cast will be available on the

3 new patents granted to Svenska Aerogel

Nasdaq First North-listed Svenska Aerogel is strengthening the patent portfolio with an additional 3 patents for the use of Quartzene®. These patents initially concern Sweden and will be expanded to Europe / globally, which strengthens Svenska Aerogel's commercial product development.The three patents relate briefly: • Filtration - absorption of formaldehyde • Filtration - absorption of ethylene • Improved printability "Working actively with our intellectual property is an important part of developing commercially strong products that are protected. These 3 new patents

INTERIM REPORT JANUARY - SEPTEMBER 2018

Positive effects of strategic efforts, challenging external factors During the third quarter, implementation of the strategic plan continued at a high pace. The quarter was also affected by challenging external factors. The sales trend was negatively affected by the hot summer, and increased raw material prices for timber continued to negatively impact the gross margin. The sales trend was also negatively impacted by the choice to decrease unprofitable sales in Skånska Byggvaror. Year-on-year Byggmax Group’s sales decreased 5.5 percent in the quarter, and profitability measured as EBITDA

Interim report, January – September 2018

Continued positive development of revenues and profitsThe third quarter in brief · Revenues increased by 11% to SEK 725 (653) million. Growth in local currencies was 4%. Change in accounting principles has affected revenues for the quarter negatively by SEK 32 million. · EBITDA increased by 10% and amounted to SEK 52.9 (48.0) million. · Profit before tax increased by 18% to SEK 37.4 (31.7) million. · Profit after tax increased by 14% to SEK 27.8 (24.3) million. · Profit per share amounted to 3.02 (2.60) SEK. The first nine months in brief · Revenues were unchanged

Interim report January-September 2018

Quarter 3, 2018 · Incoming orders amounted to SEK 817.9m (761.0), which currency adjusted is an increase of 1.2 percent compared with the same period last year. · Net sales amounted to SEK 835.2m (768.7), which currency adjusted is an increase of 2.5 percent compared with the same period last year. · Operating profit was SEK 50.6m (69.3), giving an operating margin of 6.1 percent (9.0). · Net profit was SEK 32.9m (42.9). · Earnings per share were SEK 0.94 (1.22).* January – September, 2018 · Incoming orders amounted to SEK 2,511.7m (2,341.5), which currency adjusted

Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million

Press release October 18, 2018 The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million The Board of Directors of Enzymatica AB (publ) has decided to carry out a rights issue of a maximum of SEK 98,678,187.20 with preferential rights for existing shareholders. The purpose of the rights issue is to finance continued marketing campaigns and clinical studies on the efficacy of ColdZyme besides repaying a bridge loan. The rights issue is subject to approval by an Extraordinary General Meeting to be held on November 5, 2018. Under the terms of the rights issue,

Polygiene Strengthens Marketing Department with New Hire

The appointment of Rebecka Harvyl as marketing manager will strengthen the marketing team with her additional skill set and professional background. Harvyl will be situated at the Polygiene headquarters in Malmö, Sweden.Harvyl comes with a strong background in project management within marketing where her latest employment was at Sweden’s most well-known candy store chain, Hemmakväll. She will now work with marketing responsibilities for the EMEA region, as well as oversee projects ranging from graphic production, printed materials, to social media management. ”I am looking forward to

There are no items matching the current filter
There are no more items matching the current filter
Back to top